ADC Therapeutics SA ADCT 深 滬
已收盤 08-15 16:00:00 美东时间
3.13
-0.060
-1.88%
華盛通- 最 高3.24
- 今 開3.21
- 成交量 50.00万股
- 最 低 3.095
- 昨 收 3.19
- 總市值 3.11亿
- 52周最高 3.97
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 1.05
- 委 比 -31.62%
- 總股本 9922.97万
- 歷史最高 56.59
- 量 比 0.66
- 振 幅 4.55%
- 歷史最低 0.3599
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guggenheim Reiterates Buy on ADC Therapeutics, Maintains $10 Price Target
Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $10 price target.
08-13 21:47
ADC Therapeutics Q2 Adj. EPS $(0.25) Beats $(0.39) Estimate, Sales $18.839M Beat $17.776M Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.39) by 35.9 percent. This is unchanged from the same period last year. The company reported
08-12 19:31
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Preview: ADC Therapeutics's Earnings
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings repor...
08-12 03:03
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
08-02 04:05
Aduro Clean Technologies Announces Grant of Stock Options and RSUs
Aduro Clean Technologies Inc. granted 743,500 stock options and 100,000 restricted share units (RSUs) to its directors, officers, employees, and consultants. The stock options have an exercise price of $13.50 per share and are exercisable over five years, vesting monthly over two years. The RSUs vest in three tranches over a year. All securities are subject to a four-month hold period. The granting of these options and RSUs aims to attract and re...
07-03 11:00
ADC Therapeutics files to sell 27.73M common shares by selling shareholders
ADC Therapeutics (NYSE:ADCT) filed a prospectus to sale 27.73 million shares of common stock. The company will not receive any proceeds from the sale of ordinary shares by the selling shareholder. Thi...
07-01 05:36
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global ...
06-26 23:44
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
06-21 08:35
RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $5
RBC Capital analyst Leonid Timashev maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target from $8 to $5.
06-20 21:55
